Illumina to acquire SomaLogic from Standard BioTools for $425m.

Illumina, a genomics company, agreed to acquire SomaLogic, a provider of proteomics technology, from Standard BioTools, a life sciences tools company, for $425m. "The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future. Illumina and SomaLogic have partnered closely for more than three years, and this combination increases our ability to serve our customers and accelerate our technology roadmap towards advanced biomarker discovery and disease profiling," Jacob Thaysen, Illumina CEO.